FDA Approves Gedatolisib in Breast Cancer - Top-Institutions - MDSpire

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Oncology

  • #2

    University of Washington
    University of Washington

    Seattle, WA

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

Original Source(s)

FDA Approves Gedatolisib in Breast Cancer

  • by Kathryn Wighton

  • July 14, 2026

Related Content

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.